Cantargia AB (OSTO:CANTA)

Q3 2025 Cantargia AB Earnings Call Transcript

Nov 19, 2025 / 02:00 PM GMT

Release Date Price: kr3.17 (-7.45%)

Transcript

Key Points

Positve

Cantargia AB (FRA:7V3) reported its first-ever revenues and profits in Q3 2025, driven by the Otsuka transaction.
The company received $33 million from the Otsuka deal and is eligible for up to $613 million in milestones, plus double-digit royalties.
Nadunolumab has shown promising results in pancreatic ductal adenocarcinoma (PDAC) with a median overall survival of 13.2 months.
The company has developed a robust assay to test IL-1 RAP in tumor biopsies, aiding in patient selection for future studies.
Cantargia AB (FRA:7V3) has a cash runway extending into 2028, providing financial stability for ongoing and future projects.

Negative

The Trior phase two study showed no difference in objective response rate (ORR) between the control group and those treated with nadunolumab.
The sample size for non-small cell lung cancer results was limited to only 11 patients, making it insufficient for further development.
Increased administrative costs were noted due to transaction-related expenses and leadership changes.
The company has not yet finalized the design or funding for the pivotal study in PDAC, creating uncertainty about its commencement.
The triple negative breast cancer study did not show a difference in ORR, and mature overall survival data is still pending.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CANTA.ST - Cantargia AB
Q3 2025 Cantargia AB Earnings Call
Nov 19, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Everyone and thank you for joining the presentation of our financial report for the 3rd quarter and an update from the company. My name is Hilda Steiniger and as you probably are aware, newly appointed as CEO of Ontario.

With me today, we have our, newly appointed medical officer, Doctor Wolfram Demke and our CFO Patrick Renblatt.

Slide 4, We reported this morning our interim report for the 3rd quarter and the 1st 9 months of the year. It has indeed been a transformative period for the company with the Otsuka transaction as the main event.

About the same time.

A About the same period, we communicated the overall primary endpoint from our Trior phase two study on the objective response rate ORR, and the results

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.